Dr. Rosalyn Juergens is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is also an OICR Clinical Research Scholar and a member of the Escarpment Cancer Research Institute. She chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario, and is a member of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee.
Dr. Juergens’ clinical expertise is in lung and esophageal cancer. Her areas of research expertise involve improving therapeutics and diagnostics in cancer. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. She has been a principal investigator on numerous clinical trials assessing immune based therapy in lung cancer as well as esophagogastric cancer. She has been using PD-1 inhibitors since their initial phase I trials. She is a highly sought teacher in the field of immunotherapy and has been an invited speaker across the world. She has published her work in prominent journals including such as the Journal of Clinical Oncology and Cancer Discovery.
Dr. Juergens received her medical degree from Georgetown University in Washington, D.C. She was an intern and resident in the Osler Internal Medicine Training Program at The Johns Hopkins Medical Institute. She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies as well at Johns Hopkins. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University.
Let's spread the word about Immunotherapy! Click to share this page with your community.